N-Cadherin Expression and Epithelial-Mesenchymal Transition in Pancreatic Carcinoma

Sanae Nakajima, Ryuichiro Doi, Eiji Toyoda, Shoichiro Tsuji, Michihiko Wada, Masayuki Koizumi, Siddartha S. Tulachan, Daisuke Ito, Kazuhiro Kami, Tomohiko Mori, Yoshiya Kawaguchi, Koji Fujimoto, Ryo Hosotani, and Masayuki Imamura

Department of Surgery and Surgical Basic Science, Graduate School of Medicine, Kyoto University, Kyoto, Japan

ABSTRACT

Purpose: Loss of intercellular adhesion and increased cell motility promote tumor cell invasion. In the present study, E- and N-cadherin, members of the classical cadherin family, are investigated as inducers of epithelial-to-mesenchymal transition (EMT) that is thought to play a fundamental role during the early steps of invasion and metastasis of carcinomas. Cell growth factors are known to regulate cell adhesion molecules. The purpose of the study presented here was to investigate whether a gain in N-cadherin in pancreatic cancer is involved in the process of metastasis via EMT and whether its expression is affected by growth factors.

Experimental Design: We immunohistochemically examined the expression of N- and E-cadherins and vimentin, a mesenchymal marker, in pancreatic primary and metastatic tumors. Correlations among the expressions of N-cadherin, transforming growth factor (TGF)β, and fibroblast growth factor 2 were evaluated in both tumors, and the induction of cadherin and vimentin by growth factors was assessed in cultured cell lines.

Results: N-cadherin expression was observed in 13 of 30 primary tumors and in 8 of 15 metastatic tumors. N-cadherin expression correlated with neural invasion (P = 0.008), histological type (P = 0.043), fibroblast growth factor expression in primary tumors (P = 0.007), and TGF expression (P = 0.004) and vimentin (P = 0.01) in metastatic tumors. Vimentin, a mesenchymal marker, was observed in a few cancer cells of primary tumor but was substantially expressed in liver metastasis. TGF stimulated N-cadherin and vimentin protein expression and decreased E-cadherin expression of Panc-1 cells with morphological change.

Conclusion: This study provided the morphological evidence of EMT in pancreatic carcinoma and revealed that overexpression of N-cadherin is involved in EMT and is affected by growth factors.

INTRODUCTION

Cadherins, calcium-dependent cell adhesion molecules, are involved in maintaining the epithelial structure of a variety of tissues and play important roles in embryonic development and maintenance of normal tissue architecture (1). It has been well established that E-cadherin plays a role in tumor progression and metastasis, because loss of E-cadherin expression has been found to correlate with an invasive and undifferentiated phenotype in many carcinomas including pancreatic carcinoma (2–7). N-cadherin (neural cadherin), another adhesion molecule, is associated with a heightened invasive potential in cancer. A recent study demonstrated that overexpression of N-cadherin in breast cancer correlates with invasiveness as a result of N-cadherin-mediated interactions between cancer and stromal cells (8). The phenotype of breast cancer cell lines was found to undergo dedifferentiation from epithelial to mesenchymal as a result of N-cadherin transfection without a loss of E-cadherin expression (9). In squamous epithelial cells, expression of N-cadherin produced a scattered phenotype with an epithelial-to-mesenchymal transition (EMT) in association with a reduction in E- and P-cadherins (10). In N-cadherin transfected breast cancer cells, N-cadherin promotes motility and invasion, but the reduction in the expression of E-cadherin does not necessarily correlate with either of these two (11). These findings indicate that N-cadherin, functioning as adhesion molecules, may be more important than E-cadherin for metastasis and invasion.

Changes in cell adhesion, regulated by environmental signals such as growth factors, appear to be necessary for dynamic cellular movement and maintenance of tissue patterning. Growth factors and cytokines can modulate expression of E-cadherin; for example, transforming growth factor (TGF)β induces dedifferentiation of the phenotype of normal mammary epithelial cells from epithelial to fibroblastic, which correlates with a reduction in the expression of E-cadherin (12). Fibroblast growth factor (FGF)-1 and FGF-2 enhance E-cadherin-mediated cell-cell adhesion and reduce in vitro invasion in cancer cells (13, 14). Furthermore, N-cadherin-dependent motility may be mediated by FGF receptor signaling, but the mechanism of regulating cadherin expression is not known (8, 11).

Pancreatic cancer has a very poor prognosis, and the 5-year survival rate for patients who underwent surgical resection is reported to be only 8.1–24.0% (15–18). The reasons for such poor prognosis are a high incidence of local recurrence, lymph node metastasis, hepatic metastasis, and peritoneal dissemination. As pancreatic cancer progresses, a high rate of neural...
invasion, which is associated with poor prognosis, is observed and increases even more as the cancer becomes undifferentiated (19–21). One of the reasons that pancreatic cancer extends along the neural bands is probably due to the abundance of nerves inside and around the pancreas. Another possibility is that the adhesion molecules, which define the affinity of cancer cells to neural band, subsequently affect the motility of cancer cells. One study of the relationship between neural cell adhesion molecule expression and neural invasion found no correlation (22). Because N-cadherin is highly prevalent in neuronal tissues and is also found in fibroblasts, muscles, vascular endothelium, and peritoneal mesothelial cells (23–26), it is important to investigate the association between the expression of N-cadherin in pancreatic cancer and its invasiveness including neural invasion.

The purpose of this study presented here was to investigate whether a gain in N-cadherin in pancreatic cancer is involved in the process of metastasis via EMT and whether its expression is affected by growth factors. To this end, the expression of N- and E-cadherins and vimentin, a mesenchymal marker, was immunohistochemically examined in pancreatic primary and metastatic tumors. In addition, clinicopathological parameters including patient prognosis were assessed in relation to N-cadherin expression. Correlations among the expressions of N-cadherin, TGFβ, and FGF were evaluated in both primary and metastatic tumors. Finally, the induction of cadherin and vimentin by growth factors was examined in cultured cell lines.

**MATERIALS AND METHODS**

**Antibodies and Growth Factors.** Monoclonal mouse immunoglobulin (IgG) antibodies to N-cadherin were purchased from Zymed Laboratories Inc. (San Francisco, CA), E-cadherin from Takara Bio Inc. (Shiga, Japan), and vimentin from Santa Cruz Biotechnology (Santa Cruz, CA). Polyclonal antibodies to molecular expression and neural invasion found no correlation (22). Because N-cadherin is highly prevalent in neuronal tissues and is also found in fibroblasts, muscles, vascular endothelium, and peritoneal mesothelial cells (23–26), it is important to investigate the association between the expression of N-cadherin in pancreatic cancer and its invasiveness including neural invasion.

The purpose of this study presented here was to investigate whether a gain in N-cadherin in pancreatic cancer is involved in the process of metastasis via EMT and whether its expression is affected by growth factors. To this end, the expression of N- and E-cadherins and vimentin, a mesenchymal marker, was immunohistochemically examined in pancreatic primary and metastatic tumors. In addition, clinicopathological parameters including patient prognosis were assessed in relation to N-cadherin expression. Correlations among the expressions of N-cadherin, TGFβ, and FGF were evaluated in both primary and metastatic tumors. Finally, the induction of cadherin and vimentin by growth factors was examined in cultured cell lines.

**MATERIALS AND METHODS**

**Antibodies and Growth Factors.** Monoclonal mouse immunoglobulin (IgG) antibodies to N-cadherin were purchased from Zymed Laboratories Inc. (San Francisco, CA), E-cadherin from Takara Bio Inc. (Shiga, Japan), and vimentin from Santa Cruz Biotechnology (Santa Cruz, CA). Polyclonal antibodies to FGF2 and TGFβ were obtained from Santa Cruz Biotechnology. Human recombinant FGF-2 and TGFβ were obtained from R&D Systems (Minneapolis, MN).

**Patients and Paraffin-Embedded Tissue Sample.** Thirty tissue samples were obtained from patients with primary pancreatic cancer who were operated on at the Department of Surgery and Surgical Basic Science of Kyoto University Hospital (Kyoto, Japan) between January 1997 and June 2000. The average age at surgery was 66.3 years (range, 46–76). We chose only those patients who had survived at least 60 days after surgery to exclude perioperative mortality-related bias. Follow-up data were updated on December 31, 2002 (median follow-up was 10.1 months; range, 3.0–43.9). Tissue samples were fixed with 10% formaldehyde in PBS, embedded in paraffin, and cut into consecutive 4-μm-thick sections. All of the tumors were diagnosed and confirmed as invasive ductal adenocarcinomas at the Department of Pathology, Kyoto University Hospital. Pancreatic cancer was staged according to the Putnam (Unio Internationale Contra Cancrum) system (27) and additionally characterized with the Japan Pancreas Society classification (28). Fifteen samples of hepatic metastasis were collected separately. A total of 45 samples were used for immunohistochemistry of N- and E-cadherins, vimentin, TGFβ, and FGF-2.

**Immunohistochemistry.** Because the avidin-biotin complex method using various dilution series of primary and secondary antibodies did not lead to any positive N-cadherin immunoreaction, the Catalyzed Signal Amplification System was implemented. The Catalyzed Signal Amplification System is up to 1000 times more sensitive than the usual immunoenzymatic detection systems and allows for the detection of small amounts of antigen with monoclonal antibodies, which are normally considered unsuitable for paraffin sections (29). The standard immunoperoxidase technique was used for E-cadherin, TGFβ, FGF-2, and vimentin.

Paraffin sections were dewaxed in three changes of xylene, followed by rinsing in graded ethanol and finally three courses of dehydration with double-distilled water. For antigen retrieval, the slides were pretreated in a Target Retrieval Solution (S3307; DAKO, Carpinteria, CA), heated in a hot water bath for 20 min at 95°C, followed by cooling down at room temperature for 20 min. Next, they were soaked in 3% H2O2 for 10 min and then treated with an endogenous biotin blocking reagent (X0590; DAKO) to block endogenous peroxidase activities. Next, the sections were incubated for 10 min at room temperature with 50 mM Tris-HCl buffer containing 0.15 M NaCl and 0.1% Tween 20 (TBST). The N-cadherin antibody diluted to 1:1000 with antibody dilution solution (DAKO) was applied to the section followed by incubation for 15 min at room temperature. The sections were washed with TBST three times for 5 min at room temperature, after which the Catalyzed Signal Amplification System (K1500; DAKO) was used to detect N-cadherin. Staining was completed with 30-s incubation with diaminobenzidine-tetrahydrochloride. E-cadherin, TGF β, FGF-2 and vimentin primary antibodies were diluted to 1:100 and incubated at 4°C overnight. After being washed three times in PBS, the sections were incubated with the appropriate peroxidase-labeled secondary antibodies for 1 h at room temperature and incubated with streptavidin-peroxidase complex. The sections were then washed again and developed for 1–10 min with diaminobenzidine-tetrahydrochloride in 50 mM Tris-buffered saline containing 20 μl of 30% H2O2 as the substrate. Finally, all of the sections were rinsed with distilled water and counterstained with Mayer’s hematoxylin and mounted. To confirm the specificity of the results, we exposed nonspecific IgG as the primary antibody to several samples, and none of them showed any immunoreaction.

**Evaluation of Immunostaining.** Two investigators (S. N., S. T) simultaneously assessed the results of immunostaining without knowledge of the patient clinicopathological details. The intensity of staining was evaluated with the method described previously (5, 22, 30–32). The samples were then divided into two groups based on the intensity of staining of N-cadherin in cancer cells, a low N-cadherin group in which ≤20% of the cancer cells were stained and a high N-cadherin in which >20% were stained. E-cadherin expression in the tumors was graded according to the proportion of positive cells. E-cadherin expression was considered to be normal if >90% of cancer cells exhibited a staining pattern similar to that in normal epithelial cells, and sections with <10% of the cancer cells stained or with complete absence of staining were classified as reduced pattern. The intensities of FGF-2, TGFβ, and vimentin...
staining were also divided into two groups in the same way as that of N-cadherin staining.

**Cells.** Five human pancreatic cancer cell lines, AsPC-1, BxPC-3, Capan-2, Miapaca-2, and Panc-1, were purchased from American Type Culture Collection (Rockville, MD). Cells were grown in monolayer culture in RPMI 1640 (Life Technologies Inc., Gaithersburg, MD) containing 10% fetal bovine serum and antibiotics (100 units/ml penicillin and 100 μg/ml streptomycin) at 37°C in a humidified atmosphere composed of 95% air and 5% CO₂.

After the cells had been incubated for 24 h at 37°C, fresh serum-free medium was added alone or supplemented with 5 or 10 ng/ml of FGF-2 or TGFβ. The cells were then kept for an additional 24–48 h at 37°C. For the activation of the FGF receptor, 1 μg/ml of heparin was added to the FGF-2. Protein expression of N-, E-cadherin, and vimentin with or without FGF and TGFβ treatment was evaluated by using Western blot and immunocytochemical analysis.

**Protein Extraction and Western Blotting.** Cells were harvested and lysed with radioimmunoprecipitation assay buffer [10 mM PBS (pH 7.4), 0.1% NP40, 0.5% sodium deoxycholate, and 0.1% SDS containing 1 mM of phenylmethylsulfonyl fluoride and gabexate mesilate]. Total extracts were cleared by centrifugation at 14,000 for 10 min at 4°C, and the extracted protein was then subjected to Western blotting as described previously (3). Fifty-μg aliquots of protein were loaded onto 7.5% SDS-polyacrylamide gels and transblotted to a 0.45-

**RESULTS**

**Overexpression of N-Cadherin and Reduced Expression of E-Cadherin in Pancreatic Cancer Tissue.** The staining of N-cadherin in primary pancreatic cancer tissue was mainly identified in the cytoplasm of cancer cells, infiltrating cells, and neural bands (Fig. 1A). In noncancerous tissues, acinar, ductal, and islet cells were not stained with N-cadherin. Thirteen of the 30 pancreatic cancers (43%) were positive for N-cadherin expression. In metastatic liver tumors, N-cadherin immunoreactivity was strongly identified in noncancerous hepatic cells as well as in the cytoplasm of metastatic cancer cells (Fig. 1, B and C). Eight of 15 metastatic liver tumors (53%) were positive for N-cadherin expression.

In primary cancer tissues, E-cadherin expression in cancer cells was heterogeneous or negative compared with that in normal epithelial tissues and was characterized by patterns with variable degrees of membrane and cytoplasmic staining (Fig. 1D and E).

**Immunocytochemical Analysis.** After the cells had been grown on glass coverslips to 50% confluence, they were washed with PBS and fixed with 100% ethanol and 100% acetic acid (9:1) for 10 min on ice. Only for vimentin processing, the cells were incubated with 2% Triton X in PBS. For all of the other processes, they were incubated with the N-, E-cadherin, and vimentin monoclonal antibody for 1 h at room temperature. Nonspecific protein was blocked with 2% normal goat serum in PBS for 30 min. After washing, Cy3-conjugated secondary antimouse IgG was applied in the dark followed by incubation for 1 h at room temperature. Finally, the cells were observed under a fluorescence microscope.

**Statistical Analysis.** Relationships between the clinicopathologic characteristics of the 30 patients with high and low N- and E-cadherins were examined with the χ² test or Fisher’s exact probability test. Survival rates were calculated with the Kaplan-Meier method, and the differences between high and low N-cadherin expression groups were evaluated with the log-rank test. The results in in vitro experiments are expressed as the mean value ± SD. Statistical differences among each time point were assessed by ANOVA. The Turkey-Kramer test for post-hoc multiple comparisons was used when ANOVA was significant. P values < 0.05 were considered statistically significant.

**Fig. 1** Immunohistochemical staining of N-cadherin and E-cadherin in primary pancreatic cancer and hepatic metastasis. A, N-cadherin expression in primary tumor; B and C, N-cadherin in hepatic metastasis (B, ×100; C, ×200); D, reduced expression of E-cadherin in primary tumor and (E) in hepatic metastasis. Staining of N-cadherin was mainly observed in the cytoplasm of cancer cells and was also found in neural bands (●) and in cell membrane of hepatocytes (●).
Twenty pancreatic cancers (66%) were found to have reduced expression of E-cadherin. This expression was preserved in the noncancerous hepatic cells but reduced in the metastatic cancer cells of the metastatic liver tumors (Fig. 1E). Reduced expression of E-cadherin was also detected in 11 metastatic liver tumors (73%).

**Correlation between N- and E-Cadherin Expression and Clinicopathological Features Including Survival Analysis.** Table 1 summarizes the relationship between N- and E-cadherin expression and the clinicopathological features of the pancreatic cancers. N-cadherin expression in primary tumors significantly correlated with the extent of intrapancreatic nerve invasion and histological grade: tumors with positive nerve invasion and poorly differentiation had higher expression of N-cadherin. The survival rates for the 13 patients with N-cadherin-positive tumors and 17 with N-cadherin-negative tumors were not significantly different (Fig. 2). Moreover, there was no significant correlation between reduced E-cadherin expression and any of the clinicopathological factors.

**Correlations among N-cadherin, E-cadherin, FGF-2, TGFβ, and Vimentin Expression in Pancreatic Cancer Tissue.** TGFβ and FGF expressions were observed in fibroblasts, islet cells, and acinar cells in noncancerous tissue, but those in cancer cells were heterogeneous (Fig. 3, A, B, D, and E). Vimentin, a mesenchymal marker, was mainly observed in fibroblasts that surrounded the cancer cells and in a few cancer cells in primary tumors (Fig. 3, C). However, vimentin expression was substantially in cancer cells of hepatic metastasis (Fig. 3, F and G).

The relationship between the expression of N-cadherin staining and those of E-cadherin, FGF2, TGFβ, and vimentin was analyzed on the basis of expressions only in cancer cells. In primary tumors, there was a significant correlation between N-cadherin expression and FGF-2: tumors with a higher expression of FGF-2 also showed higher expression of N-cadherin (Table 2). Metastatic liver tumors demonstrated significant correlations between N-cadherin and TGFβ and vimentin: tumors with a higher expression of N-cadherin and vimentin also showed a higher expression of TGFβ (Table 3). When expression of these factors in primary tumors and hepatic metastases
were compared, the expression of N-cadherin and vimentin was higher in the latter than in the former, but the difference did not reach statistical significance. No correlation could be established between overexpression of N-cadherin and reduced expression of E-cadherin.

Up-Regulation of N-Cadherin by Growth Factors in Cancer Cells. N- and E-cadherins and vimentin protein expression levels in pancreatic cancer cell lines were evaluated by Western blot analysis (Fig. 4). N-cadherin and E-cadherin were detected as a single band corresponding to the respective molecular sizes of 136 kDa and 123 kDa, which is consistent with their known molecular weight. Expression levels of N- and E-cadherin varied among five pancreatic cancer cell lines. N-cadherin was expressed in BxPC-3, Panc-1, and more strongly in Capan-2, whereas E-cadherin expression was observed in the four cell lines except MI-APaCa-2. Vimentin was detected as a single band corresponding to the molecular size of 56 kDa and was expressed in the four cell lines except BxPC-3.

Changes in the expression of N-cadherin, E-cadherin, and vimentin as a result of TGFβ or FGF-2 treatment was examined by Western blot analysis and immunocytochemistry. TGFβ treatment (5 ng/ml) significantly increased N-cadherin and vimentin protein expression and decreased E-cadherin expression in Panc-1 cells (Fig. 5, A and C). FGF-2 treatment (10 ng/ml) also increased N-cadherin expression in BxPC-3 cells, but E-cadherin expression was not markedly changed (Fig. 5B). Immunocytochemistry confirmed changes in N- and E-cadherin and vimentin in Panc-1 cells in response to changes in TGFβ and N-cadherin and in BxPC-3 cells in response to changes in FGF-2 (Fig. 6). Immunoreactivity for N- and E-cadherin was mainly observed in cell membrane and for vimentin in cytoplasm (Fig. 6). It was noted that TGFβ treatment caused Panc-1 cells to form scattered appearance of cell clusters. Other cell lines were refractory to the treatment with TGFβ and FGF-2.

Table 2 N-cadherin expression in primary pancreatic cancer

<table>
<thead>
<tr>
<th>N-cadherin</th>
<th>Negative</th>
<th>Positive</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>E-cadherin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normal</td>
<td>6</td>
<td>4</td>
<td>0.794</td>
</tr>
<tr>
<td>Reduced</td>
<td>11</td>
<td>9</td>
<td>0.176</td>
</tr>
<tr>
<td>TGFβ&lt;sup&gt;+&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low</td>
<td>8</td>
<td>3</td>
<td>0.007</td>
</tr>
<tr>
<td>High</td>
<td>9</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>FGF</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low</td>
<td>11</td>
<td>2</td>
<td>0.712</td>
</tr>
<tr>
<td>High</td>
<td>6</td>
<td>11</td>
<td></td>
</tr>
<tr>
<td>Vimentin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low</td>
<td>15</td>
<td>12</td>
<td></td>
</tr>
<tr>
<td>High</td>
<td>3</td>
<td>1</td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup>TGF, transforming growth factor; FGF, fibroblast growth factor.

Fig. 2 Kaplan-Meier survival curves of patients with positive and negative N-cadherin expression. There was no statistical difference between the two groups (log-rank P = 0.199).

Fig. 3 Immunohistochemical staining of transforming growth factor (TGFβ), fibroblast growth factor (FGF2), and vimentin in primary pancreatic cancer and hepatic metastasis. A and D, TGFβ; B and E, FGF2; C, F, and G, vimentin (F and G were same staining; F, ×100; G, ×200). A–C, primary tissue; D–G, hepatic metastasis. TGFβ and FGF2 expressions in cancer cells were heterogeneous. Vimentin was mainly observed in fibroblasts that surrounded the cancer cells and in a few cancer cells in primary tumors.
DISCUSSION

Important steps in the development of metastasis and local recurrence in vivo have been linked to enhanced cell-cell adhesion or cell-matrix adhesion in the tumor itself or to enhanced cancer cell extraction at different sites (4). Analysis of adhesion molecules in human cancer cell lines suggested that those molecules might influence the migration of tumor cells (33). To infiltrate host tissues, cancer cells of epithelial origin have to separate from the tumor mass by breaking their cell-cell contacts, also known as adherens functions (34, 35). Various studies of clinical tumor tissue samples and tumor cell lines demonstrated that reduced expression of E-cadherin is associated with tumor progression and enhanced cell invasiveness (36–38).

Acquisition of metastatic phenotype of cancer cells consists of multiple steps including EMT. Changes in cadherin expression patterns may play a role in the process of EMT and cellular motility (39). Nonepithelial cadherin, including N-cadherin, was found to induce a mesenchymal-scattered phenotype associated with reduced E- and P-cadherin in squamous epithelial cells (10). In prostate cancer, especially undifferentiated tumors and metastases, E-cadherin was mostly negative, and all of the cancer cells were positive for N-cadherin in what is called “the cadherin switch” (40). The purpose of the current study was to investigate whether a gain in N-cadherin in pancreatic cancer is involved in the process of metastasis via EMT and whether its expression is affected by growth factors. In epithelial cells the resultant loss of E-cadherin and the increase in N-cadherin expression means that the tumor cells have been converted to a metastatic phenotype, for example, EMT. In the study presented here, we could not find any correlation between N- and E-cadherin expression in primary pancreatic or in metastatic tumors. An N-cadherin transfection study of breast cancer cells demonstrated recently that N-cadherin promotes motility and invasion and that a reduced expression of E-cadherin does not necessarily correlate with motility or invasion (11). N-cadherin itself might have the potential to promote tumor progression and metastasis, because in our study overexpression of N-cadherin and reduced expression of E-cadherin was much more evident in metastatic than in primary tumors. In addition, vimentin, a mesenchymal marker, was strongly expressed in cancer cells of hepatic metastasis, which in turn was significantly associated with the expression of N-cadherin. Although it is very difficult to provide firm evidence of EMT in cancer tissue, these results suggest that during the metastatic process, EMT may occur, and pancreatic cancer cells may convert to a metastatic phenotype so that the process is related to the changes in cadherin expression.

A number of studies have shown that epithelial cells can be induced to scatter in response to environmental signals such as growth factors (35, 41, 42). It was shown that TGFβ induces a mesenchymal transdifferentiation and modulates E-cadherin expression in epithelial cells (34, 43, 44). Transfection of N-cadherin into breast cancer cells resulted in increased cell migration and invasion, which was greatly enhanced by the

### Table 3 N-cadherin expression in hepatic metastasis.

<table>
<thead>
<tr>
<th>N-cadherin</th>
<th>Negative (n = 7)</th>
<th>Positive (n = 8)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>E-cadherin</td>
<td></td>
<td></td>
<td>0.184</td>
</tr>
<tr>
<td>Normal</td>
<td>3</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Reduced</td>
<td>4</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>TGFβ*</td>
<td>Low (n = 7)</td>
<td>6</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>High (n = 8)</td>
<td>1</td>
<td>7</td>
</tr>
<tr>
<td>FGF2</td>
<td>Low (n = 6)</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>High (n = 9)</td>
<td>5</td>
<td>4</td>
</tr>
<tr>
<td>Vimentin</td>
<td>Low (n = 10)</td>
<td>7</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>High (n = 5)</td>
<td>0</td>
<td>5</td>
</tr>
</tbody>
</table>

*TGF, transforming growth factor; FGF, fibroblast growth factor.

Fig. 4 Western blot analysis of E-cadherin, N-cadherin, and vimentin in five pancreatic cancer cell lines. Thirty μg of total proteins extracted from cancer cells were loaded onto each lane.

Fig. 5 Western blot analysis of changes in N-cadherin, E-cadherin, and vimentin expression by in transforming growth factor (TGF)β and fibroblast growth factor (FGF)2 treatment in pancreatic cancer cells. A, Panc-1 cells were incubated with 5 ng/ml TGFβ for 0, 24, and 48 h. B, BxPC-3 cells were incubated with 10 ng/ml FGF2 for 0, 24, and 48 h. Fifty μg of total proteins were loaded. C, quantitative analysis with image intensifier. n = 3; *, significant changes against control (ANOVA). N-cadherin and vimentin expressions were significantly induced, and E-cadherin expression was reduced by 48 h of TGFβ in Panc-1 cells. N-cadherin expression was induced, but E-cadherin and vimentin expressions were not changed by 24 h of FGF2 in BxPC-3 cells; bars, ±SD.
presence of FGF-2 and accompanied by up-regulation in matrix metalloproteinase-9 activity (8, 11). In our study, we investigated the correlation between the expression of growth factors and cadherin in pancreatic cancer cells in connection with EMT. In primary tumors, there was a significant correlation between N-cadherin expression and FGF-2. In metastatic liver tumors, there were also significant correlations between N-cadherin and TGFβ/H9252 and vimentin: metastatic tumors with a higher expression of TGFβ/H9252 also had a higher expression of N-cadherin and vimentin was found in Panc-1 cells, and high expression of N-cadherin was observed in BxPC-3 cells. Note that TGFβ treatment resulted in scattered appearance of cell clusters.

Studies in neurite extension indicated that N-cadherin promotes cell motility that is dependent on the adhesive function of N-cadherin (45). Pancreatic cancer easily extends along the abundant nerve shafts inside the pancreas. Several studies demonstrated that the extent of perineural invasion correlates with tumor differentiation in pancreatic cancer (18–22). Our results show that N-cadherin expression significantly correlates with intrapancreatic neural invasion and tumor differentiation. In prostate cancer, N-cadherin was found to be exclusively expressed in the poorly differentiated area (40). These results indicate that N-cadherin may be responsible for pancreatic cancer extension through the intrapancreatic nerve bundles as an early step in extrapancreatic invasion.

In our study, N-cadherin expression of cancer cells was predominantly observed in a cytoplasmic but not a membranous pattern in primary pancreatic tumors. N-cadherin was ubiquitously present in the cell membrane of noncancerous hepatic cells, but it was present in the cytoplasm of the cancer cells in hepatic metastasis as well. N-cadherin showed an intense presence in the regions of cell-cell contact in mesothelioma, but staining was characterized by a cytoplasmic pattern in the spindle cell area. This difference between cadherin expression in epithelioid and spindle cell areas may reflect differences in the adhesive nature of the tumor cell population (30). The extracellular domain of a cadherin promotes cell-cell adhesion, whereas the cytoplasmic domain serves to link the cadherin to the cytoskeleton via interactions with catenin and is critical for the adhesive function of the cadherin (46). This suggests that cytoplasmic cadherin has a possibility to promote cell motility and strengthen cell-cell adhesion.

In conclusion, the study reported here provided morphological evidence of the occurrence of EMT in pancreatic cancer cells. These findings suggest that N-cadherin expression may play a role in the progression of pancreatic cancer through the promotion of cell motility and the establishment of cell-cell adhesion.
N-Cadherin Expression in Pancreatic Cancer

carcinoma and found that overexpression of N-cadherin is involved in EMT and is affected by growth factors. Because EMT is an important process in the invasion and metastasis of malignant tumor cells (31, 47, 48), it is possible that N-cadherin is the adhesion molecule not only to acquire the fibroblastic morphology of EMT but also to obtain invasive and metastatic potential. To confirm this, it will be necessary to perform an N-cadherin transfection study with an invasion and motility assay.

ACKNOWLEDGMENTS

We thank Dr. Masanori Kitaichi, a professor of the Clinical Department of Pathology in our university hospital, who supervised the immunohistochemistry of this study and checked the stainings.

REFERENCES

N-Cadherin Expression and Epithelial-Mesenchymal Transition in Pancreatic Carcinoma

Sanae Nakajima, Ryuichiro Doi, Eiji Toyoda, et al.